These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24362326)

  • 1. EZH2: biology, disease, and structure-based drug discovery.
    Tan JZ; Yan Y; Wang XX; Jiang Y; Xu HE
    Acta Pharmacol Sin; 2014 Feb; 35(2):161-74. PubMed ID: 24362326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
    Simon JA; Lange CA
    Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
    Tiffen J; Gallagher SJ; Hersey P
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure, mechanism, and regulation of polycomb-repressive complex 2.
    Moritz LE; Trievel RC
    J Biol Chem; 2018 Sep; 293(36):13805-13814. PubMed ID: 28912274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
    Deb G; Thakur VS; Gupta S
    Epigenetics; 2013 May; 8(5):464-76. PubMed ID: 23644490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the PRC2 complex and application to drug discovery.
    Shi Y; Wang XX; Zhuang YW; Jiang Y; Melcher K; Xu HE
    Acta Pharmacol Sin; 2017 Jul; 38(7):963-976. PubMed ID: 28414199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EZH2 for cancer therapy: progress and perspective.
    Han Li C; Chen Y
    Curr Protein Pept Sci; 2015; 16(6):559-70. PubMed ID: 25854924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators.
    Danishuddin ; Subbarao N; Faheem M; Khan SN
    Drug Discov Today; 2019 Jan; 24(1):179-188. PubMed ID: 30031878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
    Cook N; Chen J; Zhou J; Wu D
    Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.
    Crea F; Fornaro L; Bocci G; Sun L; Farrar WL; Falcone A; Danesi R
    Cancer Metastasis Rev; 2012 Dec; 31(3-4):753-61. PubMed ID: 22711031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
    Katoh M
    Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
    Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
    Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.